Bristol-Myers Squibb Co (BMY.N) Key Developments |
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

24 Jun 2016
Change (% chg)

$-2.03 (-2.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb’s first collaboration product candidate
Wednesday, 15 Jun 2016 02:48am EDT 

PeptiDream Inc <4587.T>: Says it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS) . Says this is the first program to enter clinical testing out of the discovery collaboration between the two companies .Says the molecule being advanced in clinical testing was discovered by Bristol-Myers Squibb starting from an active lead macrocyclic compound identified by Peptidream using its PDPS technology and provided to BMS for further optimization.  Full Article

Bristol-Myers announces phase 2 data for Opdivo studies
Friday, 10 Jun 2016 02:30am EDT 

Bristol-Myers Squibb Co : Says Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients . Says primary endpoint of objective response rate (orr) per an independent radiologic review committee (irrc) was 66.3% . Says safety profile of Opdivo in checkmate -205 was consistent with previously reported data in this tumor type .Says Opdivo indicates benefit in heavily pre-treated classical Hodgkin lymphoma patients in phase 2, single-arm pivotal trial.  Full Article

Bristol-Myers Squibb declares qtrly dividend of $0.38/shr
Tuesday, 7 Jun 2016 04:15pm EDT 

Bristol-Myers Squibb Co :Declared a quarterly dividend of $0.38 per share on $0.10 par value common stock of corporation.  Full Article

Bristol-Myers Squibb, MD Anderson announce new collaboration focused on lung cancer
Tuesday, 7 Jun 2016 06:59am EDT 

Bristol-Myers Squibb Co : Bristol-Myers Squibb and MD Anderson announce new research collaboration in immuno-oncology focused on lung cancer .Bristol-Myers Squibb - collaboration to support Phase 1 and 2 clinical trials testing Opdivo as monotherapy, in combination with Yervoy, or with other agents.  Full Article

Bristol-Myers Squibb presents two-year overall survival data on Opdivo
Wednesday, 18 May 2016 05:40pm EDT 

Bristol-myers Squibb Co : Two-Year overall survival data from two pivotal opdivo® (nivolumab) trials demonstrate sustained benefit in patients with advanced non-small cell lung cancer .Treatment-Related adverse events occurred in 71% and 61% of opdivo -treated patients.  Full Article

Bristol-Myers Squibb opens expanded biologics facility
Tuesday, 17 May 2016 01:00pm EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb opens expanded biologics facility .$280 million project increases workforce, "adds new capabilities".  Full Article

HTG Molecular diagnostics announces Immuno-oncology research collaboration agreement with Bristol-Myers Squibb
Thursday, 12 May 2016 04:01pm EDT 

Htg Molecular Diagnostics Inc : Htg will provide bristol-myers squibb access to its ngs-based htg edgeseq system . Companies will collaborate to develop tools for use for molecular profiling research for immuno-oncology .Htg molecular diagnostics announces immuno-oncology research collaboration agreement with bristol-myers squibb.  Full Article

Bristol-Myers says European Commission approval of Empliciti for treatment of multiple myeloma
Wednesday, 11 May 2016 02:25pm EDT 

Bristol-myers Squibb Co :Bristol-Myers squibb and abbvie announce european commission approval of empliciti(tm) (elotuzumab) for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.  Full Article

Bristol-Myers says EU advanced melanoma drug
Wednesday, 11 May 2016 11:31am EDT 

Bristol-myers Squibb Co : European Commission Approves The First And Only Immuno-Oncology Combination, Bristol-Myers Squibb's Opdivo® (Nivolumab) + Yervoy® (Ipilimumab) Regimen, For Treatment Of Advanced Melanoma .Bristol Myers Squibb Co - Opdivo + Yervoy Regimen Now Approved For Unresectable Or Metastatic Melanoma Patients, Regardless Of Braf Mutational Status.  Full Article

Bristol-Myers Squibb Co increases FY 2016 guidance
Thursday, 28 Apr 2016 06:58am EDT 

Bristol-Myers Squibb Co:Increases FY 2016 GAAP EPS guidance range from $2.30 - $2.40 to $2.37 - $2.47.Also increases FY 2016 non-GAAP EPS guidance range from $2.30 - $2.40 to $2.50 - $2.60.  Full Article

BRIEF-PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb's first collaboration product candidate

* Says it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS)